IsoPlexis Corp. engages in the development of curative medicines and personalized therapeutics. The company is headquartered in Branford, Connecticut and currently employs 290 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in building solutions to develop curative medicines and personalized therapeutics. The firm's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The firm's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. The Company’s IsoSpeak software provides automated data analysis and accelerated insights with a push-button user interface.

Industry: Laboratory Analytical Instruments Peers: Alpha Teknova Inc BNB Plus Corp PRESSURE BIOSCIENCES INC Niagen Bioscience Inc Telesis Bio Inc. Standard BioTools Inc Harvard Bioscience Inc RADNOSTIX, INC. Miromatrix Medical Inc. Thermo Fisher Scientific Inc